Q3 Earnings Forecast for Beam Therapeutics Issued By Wedbush

Key Points

• Wedbush has revised their Q3 2025 EPS estimate for Beam Therapeutics from ($1.08) to ($1.11), reflecting a negative outlook for the company.
• The consensus estimate for Beam Therapeutics’ full-year earnings stands at ($4.57) per share, with expected losses continuing into 2026.
• Despite the earnings revisions, Beam Therapeutics retains a majority "buy" rating among analysts, with the average target price set at $48.42.

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Stock analysts at Wedbush dropped their Q3 2025 EPS estimates for Beam Therapeutics in a research report issued on Tuesday, August 5th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($1.11) for the quarter, down from their previous estimate of ($1.08). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Wedbush also issued estimates for Beam Therapeutics' Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.58) EPS, Q1 2026 earnings at ($1.30) EPS, Q2 2026 earnings at ($1.45) EPS, Q3 2026 earnings at ($1.61) EPS, Q4 2026 earnings at ($1.72) EPS, FY2026 earnings at ($6.09) EPS, FY2027 earnings at ($7.38) EPS, FY2028 earnings at ($6.51) EPS and FY2029 earnings at ($2.89) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.04. Beam Therapeutics had a negative net margin of 661.31% and a negative return on equity of 43.15%. The business had revenue of $8.47 million during the quarter, compared to analysts' expectations of $13.29 million. During the same period last year, the business earned ($1.11) earnings per share. The firm's revenue was down 28.0% on a year-over-year basis.

BEAM has been the subject of several other research reports. Guggenheim cut their price target on Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Cantor Fitzgerald raised Beam Therapeutics to a "strong-buy" rating in a report on Monday, July 21st. Wells Fargo & Company cut their price target on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Finally, Barclays dropped their target price on Beam Therapeutics from $25.00 to $21.00 and set an "equal weight" rating for the company in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $48.45.

Beam Therapeutics Price Performance

Beam Therapeutics stock traded down $0.24 during mid-day trading on Thursday, hitting $17.62. 1,793,674 shares of the company's stock traded hands, compared to its average volume of 2,325,175. The firm has a 50 day simple moving average of $18.84 and a two-hundred day simple moving average of $20.98. Beam Therapeutics has a fifty-two week low of $13.52 and a fifty-two week high of $35.25. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -3.92 and a beta of 2.22.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BEAM. LPL Financial LLC increased its position in shares of Beam Therapeutics by 5.6% in the fourth quarter. LPL Financial LLC now owns 27,698 shares of the company's stock worth $687,000 after purchasing an additional 1,462 shares during the period. Norges Bank bought a new position in shares of Beam Therapeutics in the fourth quarter worth $461,000. Alliancebernstein L.P. increased its position in shares of Beam Therapeutics by 149.4% in the fourth quarter. Alliancebernstein L.P. now owns 212,804 shares of the company's stock worth $5,278,000 after purchasing an additional 127,494 shares during the period. Franklin Resources Inc. increased its position in shares of Beam Therapeutics by 42.0% in the fourth quarter. Franklin Resources Inc. now owns 21,353 shares of the company's stock worth $530,000 after purchasing an additional 6,315 shares during the period. Finally, ExodusPoint Capital Management LP bought a new position in shares of Beam Therapeutics in the fourth quarter worth $331,000. Institutional investors own 99.68% of the company's stock.

Insider Activity at Beam Therapeutics

In related news, insider Fmr Llc sold 48,374 shares of the firm's stock in a transaction on Wednesday, July 30th. The stock was sold at an average price of $20.50, for a total value of $991,667.00. Following the transaction, the insider owned 2,073,665 shares in the company, valued at approximately $42,510,132.50. This trade represents a 2.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 49,624 shares of company stock valued at $1,015,628 in the last quarter. 3.50% of the stock is currently owned by company insiders.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.